MedTrace Logo

The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI

NCT03758248 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12000

Last updated 2020-12-08

No results posted yet for this study

Summary

Dual antiplatelet therapy with aspirin and thienopyridines is an essential treatment in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplatelet treatment, some of the patients undergoing PCI develop thrombotic stent occlusion, suggesting incomplete platelet inhibition due to thienopyridine resistance. Some patients develop bleeding event because of the improper dosage and covariation. This observational study is designed for clarifying the Influence of gene polymorphism on clinical outcomes in patients undergoing PCI.

Conditions

  • Antiplatelet Therapy
  • CYP2C19 Polymorphism

Interventions

GENETIC

CYP2C19

The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19\*17 carriers) or higher (CYP2C19\*2 carriers) risk of major adverse cardiovascular events.

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    lead OTHER

Principal Investigators

  • Yujie Zhou, PhD,MD · Beijing Anzhen Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2021-08-31
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03758248 on ClinicalTrials.gov